FOR SUPPORT, CALL 1-866-APF-3635 (273-3635)
(NORD) broke previous records with its 2019 Rare Diseases & Orphan Products Breakthrough Summit
Thanks to our supporters the APF has recently earned over $800 from amazonsmile!
Scenesse was approved by the FDA on October 8 as a treatment to increase pain-free time in the light for patients with EPP.
The FDA has granted APPROVAL for Afamelanotide (Scenesse) for the treatment of Erythropoietic Protoporphyria!
Submissions are being accepted for travel stipends to attend the 2020 Rare Disease Week
The set date for the FDA decision regarding approval of Scenesse is 10 days away.
The ICPP meeting held in Milan, Italy, September 8-11, was a global success!
